Vireo Growth (VREOF) Income from Continuing Operations (2020 - 2026)
Vireo Growth (VREOF) reported Income from Continuing Operations of 22500000.0 for Q1 2026, down 246.15% on a YoY basis from 15394736.84 in Q1 2025, and up 33.39% sequentially from 33778228.0 in Q4 2025.
Vireo Growth (VREOF) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Income from Continuing Operations data on file, last reported at 22500000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 246.15% year-over-year to 22500000.0; the trailing twelve-month figure through Mar 2026 stood at 97511118.0 (down 250.81% YoY), and the FY2025 full-year result was 81519908.0, down 191.06% from the prior year.
- Income from Continuing Operations advanced to 22500000.0 in Q1 2026, from 33778228.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 668411.0 in Q2 2024 to a low of 33778228.0 in Q4 2025.
- A 5-year average of 11678127.12 and a median of 8468970.0 in 2023 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations surged 90.95% in 2024 and sank 2134.26% in 2025, its largest moves.
- Tracing VREOF's Income from Continuing Operations over 5 years: stood at 9290798.0 in 2022, then soared by 75.54% to 2272837.0 in 2023, then plunged by 590.82% to 15701281.0 in 2024, then slumped by 115.13% to 33778228.0 in 2025, then soared by 33.39% to 22500000.0 in 2026.
- Business Quant data shows VREOF's Income from Continuing Operations at 22500000.0 in Q1 2026, 33778228.0 in Q4 2025, and 26298861.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | -22.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.50 Mn |
| Dec 31, 2025 | -33.78 Mn |
| Sep 30, 2025 | -26.30 Mn |
| Jun 30, 2025 | -14.93 Mn |
| Mar 31, 2025 | -6.50 Mn |
| Dec 31, 2024 | -15.70 Mn |
| Sep 30, 2024 | -4.93 Mn |
| Jun 30, 2024 | -668,411.00 |
| Mar 31, 2024 | -6.71 Mn |
| Dec 31, 2023 | -2.27 Mn |
| Sep 30, 2023 | -5.73 Mn |
| Jun 30, 2023 | -7.39 Mn |
| Mar 31, 2023 | -8.47 Mn |
| Dec 31, 2022 | -9.29 Mn |
| Sep 30, 2022 | -9.57 Mn |
| Jun 30, 2022 | -6.10 Mn |
| Mar 31, 2022 | -17.68 Mn |
| Dec 31, 2021 | -14.09 Mn |
| Sep 30, 2021 | -6.84 Mn |
| Jun 30, 2021 | -6.99 Mn |